



# REPRIEVE Insights

Quarterly Updates on Milestones and Discoveries



## July 2024 Table of Contents

- [What's New From REPRIEVE?](#)
- [In the Spotlight](#)
- [SCCT Clinical Trials and Registries Award](#)
- [Message from Kathleen Fitch](#)
- [Welcome to the REPRIEVE team, Sarah!](#)
- [New Recommendations for the Use of Statin Therapy in People with HIV](#)
- [REPRIEVE Team Presentations at AIDS 2024](#)
- [Two New Manuscripts Hot off the Press!](#)
- [REPRIEVE at the ACTG Network Meeting](#)
- [Help Us Spread the Word!](#)
- [Stay Tuned: REPRIEVE Request for Proposals](#)
- [We Need Your Help to Share Impacts of REPRIEVE!](#)
- [REPRIEVE Results Sharing](#)

---

## What's New From REPRIEVE?

**It has been an exciting start to the summer for REPRIEVE!**

Since our last newsletter, one of our very own REPRIEVE Community Advisory Board members, Alicia Diggs, was featured in POZ magazine, sharing her passion for diversifying clinical trials. The European AIDS Clinical Society (EACS) announced interim guidance on the use of statin therapy for the primary prevention of heart disease in people living with HIV, further integrating the results of REPRIEVE into global clinical guidelines. Additionally, members of REPRIEVE attended the ACTG Annual Network Meeting in Washington D.C. and will deliver presentations at the AIDS 2024 Conference this week.

This month, we also have a special message from Kathleen Fitch, who has played an integral role in the REPRIEVE Trial and has transitioned on to a new role. We are so grateful for all of Katie's work and dedication, and we wish her all the best in her new endeavor.

Sincerely,  
REPRIEVE Leadership

**In the Spotlight:**  
**Alicia Diggs, Community Advisory Board Member**



We are proud to share that Alicia Diggs, a REPRIEVE Community Advisory Board member, was recently featured in the July/August issue of POZ Magazine! In the feature, Alicia discusses the importance of diverse participation in clinical trials and research, particularly the representation of female participants. To read the full article, click [here](#).

Alicia, thank you for sharing your story and for all of your contributions to REPRIEVE!

**Gerald Bloomfield, REPRIEVE Cardiologist**



REPRIEVE team member Dr. Gerald Bloomfield was recently featured in a profile by the Duke Global Health Institute titled "Understanding the Link Between HIV and Heart Disease." Click [here](#) to read the full article and learn more about Dr. Bloomfield's research.

Dr. Bloomfield, we are grateful for all that you do for REPRIEVE and beyond!

## SCCT Clinical Trials and Registries Award

Congratulations to Márton Kolossváry whose abstract, "Pitavastatin reduces noncalcified coronary artery plaque via procollagen PCOLCE, independently of LDL lowering: an analysis of the REPRIEVE mechanistic substudy," was selected as runner-up for the prestigious Clinical Trials and Registries Award at the Annual Scientific Meeting of the Society of Cardiovascular CT (SCCT) in Washington, D.C.!

Márton presented this abstract during the Best Original Science session on Saturday, July 20, during the SCCT 2024 meeting. Congratulations, Márton!

## Message from Kathleen Fitch



I am writing to share some news regarding my professional journey. After the incredibly rewarding experience as the Project Manager on REPRIEVE, I am excited to announce that I have transitioned to a new role at the Massachusetts General Hospital in Mongan Institute where I am working as the Project Director in the Center for Aging and Serious Illness (CASI).

At CASI I am directing a multicenter trial to improve the care for aging adults with complex illnesses. I will also be able to continue to some of the work in HIV and aging that I have done in the past. Working on REPRIEVE has been a remarkable journey, largely due to the invaluable collaborations with so many individuals who contributed to the trial. I am excited about the new opportunities that lie ahead, but I will always hold dear the accomplishments we made together on REPRIEVE.

Please be assured that REPRIEVE will continue to thrive under new leadership. Sarah Chu has taken on the role of Project Manager, and Marissa Diggs is now serving as Associate Project Manager. I have full confidence in their abilities and know that they continue to uphold the high standards we have set together.

**Welcome to the REPRIEVE team, Sarah!**



We are excited to welcome Sarah Chu to the REPRIEVE team as the Project Manager of the Clinical Coordinating Center! Sarah is a clinical research nurse practitioner who has worked on research studies looking at cardiometabolic health among women living with HIV. She is a wonderful addition to our team and we are so grateful to work together. Welcome, Sarah!

## New Recommendations for the Use of Statin Therapy in People with HIV (based on *REPRIEVE* data) are Now Available!



**EACS**  
European  
AIDS  
Clinical  
Society

### **European AIDS Clinical Society (EACS) Interim Guidance on the Use of Statin Therapy for the Primary Prevention of Cardiovascular Disease in People with HIV**

These recommendations have been developed by representatives from the Comorbidities panel of the EACS Guidelines to inform the use of statin therapy for the primary prevention of cardiovascular disease in people with HIV in Europe. The guidance presented here are the best assessment of the evidence at the time of writing, and the key recommendations were formed on this basis. As new evidence emerges, the guidance will be updated accordingly.

# REPRIEVE Team Presentations at AIDS 2024



Congratulations to members of the REPRIEVE team who are presenting at the 25th International AIDS Society Conference in Munich, Germany! See below for details about these presentations, or click [here](#) for a schedule of events.

## Exploring the intersection of HIV and aging: A geroscience perspective

*Session 2 of this 3-part pre-conference series featured presentations by REPRIEVE team members*

*Kristine Erlandson, Sara Looby, and Steve Grinspoon*

Session date: 21 July 2024

Session time: 5:00-6:00 CEST

Session room: Room 5/Channel 8

## No evidence of pitavastatin effect on muscle density or area among people with HIV

*Poster Presentation by Kristine Erlandson*

Abstract code: TUPEB091

Session: Poster Exhibition

Session date: 23 July 2024

Session time: 12:00-1:00 CEST

## Abacavir is associated with elevated risk for cardiovascular events in the REPRIEVE trial

*Oral Presentation by Carl Fichtenbaum*

Abstract code: OAB3406LB

Session: Co-morbidities: The heart of the matter

Session date: 26 July 2024

Session time: 10:30-11:30 CEST

Session room: Hall B0b/Channel 5

**Two New Manuscripts Hot off the Press!**

**ORIGINAL RESEARCH****ISCHEMIC HEART DISEASE**

# Coronary Plaque in People With HIV vs Non-HIV Asymptomatic Community and Symptomatic Higher-Risk Populations



Julia Karady, MD,<sup>a,b,\*</sup> Michael T. Lu, MD, MPH,<sup>a,\*</sup> Göran Bergström, MD,<sup>c,d</sup> Thomas Mayrhofer, PhD,<sup>a,e</sup> Jana Taron, MD,<sup>a,f</sup> Borek Foldyna, MD,<sup>a</sup> Kayla Paradis, BS,<sup>a</sup> Sara McCallum, MPH,<sup>g</sup> Judith A. Aberg, MD,<sup>h</sup> Judith S. Currier, MD,<sup>i</sup> Kathleen V. Fitch, MSN,<sup>g</sup> Evelynne S. Fulda, BA,<sup>g</sup> Gerald S. Bloomfield, MD, MPH,<sup>j</sup> Edgar T. Overton, MD,<sup>k</sup> Lars Lind, MD,<sup>l</sup> Carl Johan Östgren, MD,<sup>m,n</sup> Olof Elvstam, MD,<sup>o,p</sup> Stefan Söderberg, MD,<sup>q</sup> Tomas Jernberg, MD,<sup>r</sup> Rosalie Pepe, MD,<sup>s</sup> Michael P. Dubé, MD,<sup>t</sup> David Mushatt, MD, MPH,<sup>u</sup> Carl J. Fichtenbaum, MD,<sup>v</sup> Carlos Malvestutto, MD, MPH,<sup>w</sup> Markella V. Zanni, MD,<sup>g</sup> Udo Hoffmann, MD, MPH,<sup>a,x</sup> Heather Ribaldo, PhD,<sup>y</sup> Steven K. Grinspoon, MD,<sup>g</sup> Pamela S. Douglas, MD<sup>j</sup>

Two new REPRIEVE manuscripts were recently published! The manuscript above was published in JACC: Advances and reports differences in coronary plaque between people living with HIV and people living without HIV. The final results of REPRIEVE, which incorporate data collected at study termination visits, were published in The New England Journal of Medicine as a research letter.

For more details on these manuscripts and their findings, please visit our [publications page](#).

## REPRIEVE at the ACTG Network Meeting



In June, members of the REPRIEVE Team attended the ACTG Network Meeting in Washington, D.C.!

Sara Looby delivered presentations about a new ACTG study, A5424, and during a symposium titled Health Implications of Reproductive Aging in Women with HIV, and Carlos Malvestutto presented about ACTG studies A5428 and A5389. New REPRIEVE data was also featured in a symposium presentation by Steve Grinspoon, "Residual Risk of CVD in PWH, What Can We Learn from REPRIEVE."

We enjoyed seeing many REPRIEVE site teams at the meeting this year!



## Help Us Spread the Word!

During this phase of REPRIEVE, the **Clinical Coordinating Center is focused on dedicated dissemination and education efforts to support the interpretation of REPRIEVE findings and to support the adoption and implementation of guidelines in practice.** One part of this effort is this digital quarterly newsletter, **REPRIEVE Insights: Quarterly Updates on Milestones and Discoveries.**

**Anyone** interested in staying up-to-date with REPRIEVE activities and future publications can sign up for this newsletter. To this end, please distribute the signup link (below) and/or [click here](#) to download and distribute a flyer with a QR code to ensure that as many people as possible can stay in touch with REPRIEVE.

[REPRIEVE Insights Newsletter Sign Up Form](#)

*Please share this with anyone who may be interested in receiving information about REPRIEVE. **THANK YOU!!!***



## Stay Tuned: REPRIEVE Request for Proposals

Stay tuned for an announcement from REPRIEVE about a request for proposals (RFP) . More information will be shared on our [website](#) in the fall. Check back soon!



## We Need Your Help to Share Impacts of REPRIEVE!

Results from REPRIEVE are making an impact across the globe, from changing guidelines to changing the care of people living with HIV. If you have a story about how results from REPRIEVE have changed your care or clinical practice we want to hear from you! Please reach out to Sarah Chu ([schu4@mgh.harvard.edu](mailto:schu4@mgh.harvard.edu)) or Marissa Diggs ([mdiggs@mgh.harvard.edu](mailto:mdiggs@mgh.harvard.edu)) at the REPRIEVE Clinical Coordinating Center (CCC).

## REPRIEVE Results Sharing

The REPRIEVE Trial website has a central webpage on which various REPRIEVE results materials are posted. The materials include:

- Graphical abstract of trial results
- Statin guidance for PWH
- Slide templates for presentations to providers
- Slide templates for presentations to the community
- Participant FAQs, and more!

If you are interesting sharing results from REPRIEVE in your local area or want to learn more this webpage is a





great place to visit! Go to: <https://www.reprievetrial.org/learnmore/results-of-the-repriev-trial/>.

*For future reference, all newsletters are available on the [REPRIEVE Website](#)*

### Our sponsors and collaborators



Like, comment, share, and repost!

***REPRIEVE Trial Clinical Coordinating Center***

Massachusetts General Hospital  
50 Staniford St, Suite 750  
Boston, MA USA 02114

